实控人被立案后 医美龙头昊海生科启动董事会换届

Core Viewpoint - The company, Haohai Biological Technology (昊海生科), is undergoing a board restructuring following the investigation of its actual controller, Jiang Wei, for suspected insider trading, but the company's performance remains stable and unaffected by the incident [1][2]. Group 1: Board Restructuring - Haohai Biological announced the initiation of a board restructuring process on May 10, proposing candidates for the sixth board of directors, including current chairman Hou Yongtai [1]. - The fifth board's thirty-second meeting was held on May 9, where proposals for both non-independent and independent director candidates were approved, pending shareholder meeting approval [1]. Group 2: Leadership Background - Hou Yongtai, aged 64, has a strong academic background with master's and doctoral degrees from Ohio University and postdoctoral research at the University of Pennsylvania [1]. - He has held various significant positions within the company since its establishment, including chairman and executive director, contributing to its growth in the medical aesthetics sector [1]. Group 3: Impact of Jiang Wei's Investigation - Jiang Wei, a major shareholder and actual controller, has been notified of an investigation by the China Securities Regulatory Commission for insider trading, but this has not significantly impacted the company's stock performance [2]. - Jiang Wei's wife, You Jie, remains nominated as a non-executive director candidate for the new board, indicating continuity in leadership despite the investigation [2].